Source: Pharmabiz

Phanes: US FDA grants Fast Track designation to Phanes Therapeutics' PT217 to treat patients with extensivestage SCLC

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that the US Food and Drug Administration (FDA) has granted

Read full article »

Phanes's Competitors | Phanes's News | Phanes's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Founder & CEO

Ming Wang

CEO Approval Rating

90/100

Phanes is a California-based biotechnology company that provides drug discovery, development and related services for the treatment of cancer and opthalmic diseases.